Cost‐effectiveness of control‐ IQ automated insulin delivery in adults with type 1 diabetes in Sweden
Authors' conclusion
The results indicate that Control-IQ is a cost-effective alternative for Swedish adults with T1D and could be considered for broader use in diabetes care.
Study context
- Population
- Swedish adults with T1D
- Comparison
- Control-IQ automated insulin delivery (AID) vs standard care
- Outcome
- Cost-effectiveness: incremental cost-utility ratio (SEK/QALY)
- Follow-up
- Lifetime
Methodological detailsIQVIA Core Diabetes Model, lifetime horizon, Swedish-specific cost and discount rates, clinical data from randomized trials and real-world sources
- IQVIA Core Diabetes Model
- Lifetime horizon
- Swedish-specific cost and discount rates
- Clinical data from randomized trials and real-world sources
Main finding
As reported in the abstract
Lifetime cost-utility
Quality-adjusted life years (QALYs) gained with Control-IQ
1.080
Incremental cost-utility ratio
391,705 SEK/QALY
Total direct costs higher, ICUR below Sweden's commonly accepted threshold
500,000 SEK/QALY
Further findings
Projected lifetime complication rates
- Lower projected lifetime rates of severe hypoglycaemia, renal complications, cardiovascular events and ulcer/amputation/neuropathy with Control-IQ
Sensitivity analyses
- Consistent results across different scenarios
Original publication
Cost‐effectiveness of control‐ IQ automated insulin delivery in adults with type 1 diabetes in Sweden. Diabet Med. Published 21 May 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →